ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
-1,03%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,245
0,92%
Bitcoin
61 394,58
0,96%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. OptiNose Inc (OPTN)

  7. OptiNose Inc (OPTN) Actualités

OPTN

OptiNose (OPTN)

OptiNose Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OPTN
DateHeureSourceTitreSymboleSociété
27/06/202413h00GlobeNewswire Inc.Expanded Access to XHANCE with Addition to National Commercial FormulariesNASDAQ:OPTNOptiNose Inc
18/06/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
06/06/202422h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
29/05/202421h32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
20/05/202420h33Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OPTNOptiNose Inc
17/05/202418h00GlobeNewswire Inc.Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:OPTNOptiNose Inc
14/05/202415h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OPTNOptiNose Inc
14/05/202413h00GlobeNewswire Inc.Optinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
10/05/202420h56GlobeNewswire Inc.Optinose Announces Reporting Date for First Quarter 2024 Financial ResultsNASDAQ:OPTNOptiNose Inc
09/05/202413h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OPTNOptiNose Inc
09/05/202413h00GlobeNewswire Inc.Optinose Announces $55 Million Registered Direct OfferingNASDAQ:OPTNOptiNose Inc
25/04/202413h00GlobeNewswire Inc.Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionNASDAQ:OPTNOptiNose Inc
04/04/202422h01GlobeNewswire Inc.Optinose to Present at the Needham Virtual Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
15/03/202420h34GlobeNewswire Inc.XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsNASDAQ:OPTNOptiNose Inc
07/03/202422h32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OPTNOptiNose Inc
07/03/202413h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OPTNOptiNose Inc
07/03/202413h00GlobeNewswire Inc.Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
29/02/202422h40GlobeNewswire Inc.Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
18/01/202418h00GlobeNewswire Inc.Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeNASDAQ:OPTNOptiNose Inc
06/12/202314h48Dow Jones NewsOptinose Shares Slide Premarket as FDA Extends Xhance ReviewNASDAQ:OPTNOptiNose Inc
06/12/202313h00GlobeNewswire Inc.Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCENASDAQ:OPTNOptiNose Inc
22/11/202315h00GlobeNewswire Inc.Optinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
09/11/202313h00GlobeNewswire Inc.Optinose Reports Third Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/10/202314h00GlobeNewswire Inc.Optinose Announces Reporting Date for Third Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
22/09/202315h01GlobeNewswire Inc.Optinose to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
18/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OPTNOptiNose Inc
10/08/202322h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OPTNOptiNose Inc
10/08/202313h00GlobeNewswire Inc.Optinose Reports Second Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/07/202313h00GlobeNewswire Inc.Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 MillionNASDAQ:OPTNOptiNose Inc
20/06/202319h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPTNOptiNose Inc
 Showing the most relevant articles for your search:NASDAQ:OPTN

Dernières Valeurs Consultées

COIN
BTQEUR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés